Skip to main content

Table 3 Adverse events more frequently observed in patients treated with the synergistic IFN-α and -γ combination

From: Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study

Adverse events

Frequency

%

Fever

34

32.7

Chills

13

12.5

Arthralgias

11

10.6

Anorexia

10

9.6

Asthenia

7

6.7

Diarrhea

6

5.8

Myalgias

3

2.9

Chemosis

2

1.9

Erythema

2

1.9

Vomiting

2

1.9

Palpebral edema

2

1.9

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us